Cited by 4,792Nanoparticle-Based Drug DeliveryUltrasound and Hyperthermia ApplicationsRNA Interference and Gene Delivery

The DOI matches its Crossref record; 127 of the 140 references it cites were found in a registry or an index.

Doxil® — The first FDA-approved nano-drug: Lessons learned

Barenholz, Yechezkel (Chezy)·2012·Journal of Controlled Release

DOI 10.1016/j.jconrel.2012.03.020

Open this paper in CoChat — free account

Abstract

Doxil®, the first FDA-approved nano-drug (1995), is based on three unrelated principles: (i) prolonged drug circulation time and avoidance of the RES due to the use of PEGylated nano-liposomes; (ii) high and stable remote loading of doxorubicin driven by a transmembrane ammonium sulfate gradient, which also allows for drug release at the tumor; and (iii) having the liposome lipid bilayer in a "liquid ordered" phase composed of the high-T(m) (53 °C) phosphatidylcholine, and cholesterol. Due to the EPR effect, Doxil is "passively targeted" to tumors and its doxorubicin is released and becomes available to tumor cells by as yet unknown means. This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use. It demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles. However, in spite of the large reward, ~2 years after Doxil-related patents expired, there is still no FDA-approved generic "Doxil" available.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2012.03.020

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,868
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,344
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Pharmacokinetics of Pegylated Liposomal Doxorubicin
Gabizón, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,639
Self-citation
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Self-citation
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,357
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.
Abuchowski, A., McCoy, J. R., Palczuk, N. C., Es, T. V., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,276
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212

Flagged first, then by citations

Show all 140 references

13 of the 140 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Amselem, 1993, A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use, vol. 1, 501
Barenholz, 1993, Quality control assays in the development and clinical use of liposome-based formulations, vol. 1, 527
Poste, 1983, Liposome targeting in vivo: problems and opportunities, Biol. Cell, 47, 19

Sorted by citations

Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodríguez-Torres, M. D. P., Acosta‐Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 7,038
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,382
Lipid NanoparticlesFrom Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,174
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
WICKI, A. N., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,962
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,759
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,674
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,625
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives
Liu, P., Chen, G., & Zhang, J. (2022) · Molecules · doi:10.3390/molecules27041372 · Cited by 1,334
Nanoparticles in the clinic
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
The Role of Ligands in the Chemical Synthesis and Applications of Inorganic Nanoparticles
Heuer‐Jungemann, A., Feliu, N., Bakaimi, I., Al‐Hamaly, M. A., Alkilany, A. M., Chakraborty, I., Masood, A., Casula, M. F., Κωστοπούλου, Α., Oh, E., et al. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00733 · Cited by 1,315
Smart cancer nanomedicine
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F. M., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,279
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,279
Extracellular vesicles as drug delivery systems: Why and how?
Elsharkasy, O. M., Nordin, J. Z., Hagey, D. W., de Jong, O. G., Schiffelers, R. M., Andaloussi, S. E., & Vader, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.004 · Cited by 1,235
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Gregersen, C. H., Kulkarni, J. A., Witzigmann, D., Lind, M. L., Petersson, K., & Simonsen, J. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114416 · Cited by 1,271
Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine
de Almeida, M. S., Sušnik, E., Drašler, B., Taladriz‐Blanco, P., Petri‐Fink, A., & Rothen‐Rutishauser, B. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01127d · Cited by 1,140
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Çetinel, S., Zuvin, M., Koşar, A., & Kutlu, Ö. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,136
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
The Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,068
Therapeutic efficacy of nanoparticles and routes of administration
Chenthamara, D., Sadhasivam, S., Ramakrishnan, S. G., Krishnaswamy, S., Essa, M. M., Lin, F., & Qoronfleh, M. W. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0166-x · Cited by 1,103
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 987
Bovine milk-derived exosomes for drug delivery
Munagala, R., Aqil, F., Jeyabalan, J., & Gupta, R. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.020 · Cited by 936
Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems
Yusuf, A., Almotairy, A. R. Z., Henidi, H. A., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 1,008
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 886
Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine
Lombardo, D., Kiselev, M. A., & Caccamo, M. T. (2019) · Journal of Nanomaterials · doi:10.1155/2019/3702518 · Cited by 864
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 890
Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment
Naksuriya, O., Okonogi, S., Schiffelers, R. M., & Hennink, W. E. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.090 · Cited by 856
EPR: Evidence and fallacy
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 864
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 803
Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 748
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019) · Cancers · doi:10.3390/cancers11050640 · Cited by 769
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 721
Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y. A., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 776
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Supramolecular self-assemblies as functional nanomaterials
Busseron, E., Ruff, Y., Moulin, É., & Giuseppone, N. (2013) · Nanoscale · doi:10.1039/c3nr02176a · Cited by 713
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 744
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos‐Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi‐Fainaro, R., Florindo, H. F., & Vicent, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 715
Supramolecular chemotherapy based on host–guest molecular recognition: a novel strategy in the battle against cancer with a bright future
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 681
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 688
Form Follows Function: Nanoparticle Shape and Its Implications for Nanomedicine
Kinnear, C., Moore, T. L., Rodríguez‐Lorenzo, L., Rothen‐Rutishauser, B., & Petri‐Fink, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00194 · Cited by 685
Adapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 663
Transport and interactions of nanoparticles in the kidneys
Du, B., Yu, M., & Zheng, J. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0038-3 · Cited by 668
Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine
Simón‐Yarza, T., Mielcarek, A., Couvreur, P., & Serre, C. (2018) · Advanced Materials · doi:10.1002/adma.201707365 · Cited by 661
Size-Dependent In Vivo Transport of Nanoparticles: Implications for Delivery, Targeting, and Clearance
Xu, M., Qi, Y., Liu, G. H., Song, Y., Jiang, X., & Du, B. (2023) · ACS Nano · doi:10.1021/acsnano.3c05853 · Cited by 654
The role of micelle size in tumor accumulation, penetration, and treatment
Wang, J., Mao, W., Lock, L. L., Tang, J., Sui, M., Sun, W., Cui, H., Xu, D., & Shen, Y. (2015) · ACS Nano · doi:10.1021/acsnano.5b02017 · Cited by 635
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Managing diabetes with nanomedicine: challenges and opportunities
Omid Veiseh, A., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4477 · Cited by 623
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748758 · Cited by 592
Nanocarriers for cancer-targeted drug delivery
Kumari, P., Ghosh, B., & Biswas, S. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1051049 · Cited by 619
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Liposomal Drug Delivery Systems and Anticancer Drugs
Olusanya, T. O. B., Haj-Ahmad, R., Ibegbu, M. D., Smith, J. R., & Elkordy, A. (2018) · Molecules · doi:10.3390/molecules23040907 · Cited by 605
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
Bolla, G., Sarma, B., & Nangia, A. K. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00987 · Cited by 622
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 611
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 605
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T. K., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 602
Stimuli‐responsive liposomes for drug delivery
Lee, Y. R., & Thompson, D. H. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1450 · Cited by 586
Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery
Ge, X., Wei, M., He, S., & Yuan, W. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020055 · Cited by 593
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Eeda, V., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 616
Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies
Chen, B., Cheng, T., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 587
Antibiofouling polymer interfaces: poly(ethylene glycol) and other promising candidates
Lowe, S. E., O’brien-simpson, N. M., & Connal, L. A. (2014) · Polymer Chemistry · doi:10.1039/c4py01356e · Cited by 572
Lipid Nanoparticles for Drug Delivery
Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 588
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S. S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y., Tamarkin, L., & Desai, N. P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 552
Self-citation
Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
Vangijzegem, T., Stanicki, D., & Laurent, S. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1554647 · Cited by 568
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R. A., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 577
Facing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 555
Stimuli-Responsive Nanomaterials for Biomedical Applications
Blum, A. P., Kammeyer, J. K., Rush, A. M., Callmann, C. E., Hahn, M. E., & Gianneschi, N. C. (2014) · Journal of the American Chemical Society · doi:10.1021/ja510147n · Cited by 548
Ligand-targeted liposome design: challenges and fundamental considerations
Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgiçer, B. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.09.007 · Cited by 546
Cancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 538
Safety of Nanoparticles in Medicine
Wolfram, J., Zhu, M., Yang, Y. P., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., et al. (2015) · Current Drug Targets · doi:10.2174/1389450115666140804124808 · Cited by 550
Liposomes as carriers of hydrophilic small molecule drugs: Strategies to enhance encapsulation and delivery
Eloy, J. O., de Souza, M. C., Petrilli, R., Barcellos, J. P. A., Lee, R. J., & Marchetti, J. M. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.09.029 · Cited by 547
Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review
Viegas, C., Patrício, A. B., Prata, J., Nadhman, A., Chintamaneni, P. K., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061593 · Cited by 585
Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 551
PEGylated liposomes: immunological responses
Sayed, M. M. E., Lila, A. S. A., Shimizu, T., Alaaeldin, E., Hussein, A. K., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 551
State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 540
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 525

Authors: Barenholz, Y. (.
Affiliations: Hebrew University of Jerusalem (IL)
Corresponding author: Barenholz, Yechezkel (Chezy)
ORCID: Barenholz, Yechezkel (Chezy)
Venue: Journal of Controlled Release
Publisher: Elsevier BV
Published: 2012-06
Volume: 160
Issue: 2
Pages: 117-134
ISSN: 0168-3659 (ISSN-L)
DOI: 10.1016/j.jconrel.2012.03.020
OpenAlex: W1989230986
Cited by: 4,792
References: 140
Citations by year: 2026: 415 · 2025: 541 · 2024: 462 · 2023: 405 · 2022: 444 · 2021: 441 · 2020: 436 · 2019: 303 · 2018: 324 · 2017: 284 · 2016: 243 · 2015: 188 · 2014: 174 · 2013: 106 · 2012: 23
FWCI: 8.16
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Controlled Release (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: pegylated liposomal doxorubicin, PEGylated liposomes, nanotherapeutics, doxorubicin, enhanced permeability and retention effect, passive tumor targeting, liposome circulation time, remote loading, phosphatidylcholine, cholesterol, drug release, generic drug availability
MeSH terms: Antibiotics, Antineoplastic, Chemistry, Pharmaceutical, Delayed-Action Preparations, Doxorubicin, Drug Carriers, Drug Compounding, Humans, Liposomes, Solubility, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxil® — The first FDA-approved nano-drug: Lessons learned

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks